Rocket Pharmaceuticals Total Assets Growth & History (RCKT)
Rocket Pharmaceuticals's total assets was $330.4M for fiscal 2025.
View full Rocket Pharmaceuticals company overviewRocket Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $330.4M | −$197.3M | −37.38% |
| 2024 | 2024-12-31 | $527.7M | −$38.6M | −6.82% |
| 2023 | 2023-12-31 | $566.3M | $14.5M | +2.63% |
| 2022 | 2022-12-31 | $551.8M | $54.8M | +11.02% |
| 2021 | 2021-12-31 | $497.0M | −$93.8M | −15.88% |
| 2020 | 2020-12-31 | $590.8M | $218.7M | +58.77% |
| 2019 | 2019-12-31 | $372.1M | $120.8M | +48.07% |
| 2018 | 2018-12-31 | $251.3M | $231.2M | +1147.40% |
| 2017 | 2017-12-31 | $20.1M | −$109.5M | −84.46% |
| 2016 | 2016-12-31 | $129.6M | $16.3M | +14.41% |
| 2015 | 2015-12-31 | $113.3M | $107.8M | +1952.92% |
| 2014 | 2014-12-31 | $5.5M | — | — |
Rocket Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $423.1M | $2.1M | +0.50% |
| Q1 2026 | 2026-03-31 | $285.4M | −$185.7M | −39.41% |
| Q4 2025 | 2025-12-31 | $330.4M | −$197.3M | −37.38% |
| Q3 2025 | 2025-09-30 | $368.0M | −$25.7M | −6.52% |
| Q2 2025 | 2025-06-30 | $421.0M | −$25.4M | −5.70% |
| Q1 2025 | 2025-03-31 | $471.1M | −$28.4M | −5.68% |
| Q4 2024 | 2024-12-31 | $527.7M | −$38.6M | −6.82% |
| Q3 2024 | 2024-09-30 | $393.7M | −$205.1M | −34.25% |
| Q2 2024 | 2024-06-30 | $446.4M | −$15.4M | −3.33% |
| Q1 2024 | 2024-03-31 | $499.4M | −$15.3M | −2.98% |
| Q4 2023 | 2023-12-31 | $566.3M | $14.5M | +2.63% |
| Q3 2023 | 2023-09-30 | $598.8M | $181.5M | +43.50% |
| Q2 2023 | 2023-06-30 | $461.8M | $29.9M | +6.93% |
| Q1 2023 | 2023-03-31 | $514.8M | $54.6M | +11.87% |
| Q4 2022 | 2022-12-31 | $551.8M | $54.8M | +11.02% |
| Q3 2022 | 2022-09-30 | $417.3M | −$113.0M | −21.31% |
| Q2 2022 | 2022-06-30 | $431.9M | −$103.3M | −19.30% |
| Q1 2022 | 2022-03-31 | $460.1M | −$116.3M | −20.18% |
| Q4 2021 | 2021-12-31 | $497.0M | −$93.8M | −15.88% |
| Q3 2021 | 2021-09-30 | $530.2M | $194.7M | +58.05% |
| Q2 2021 | 2021-06-30 | $535.2M | $182.1M | +51.57% |
| Q1 2021 | 2021-03-31 | $576.5M | $203.7M | +54.66% |
| Q4 2020 | 2020-12-31 | $590.8M | $218.7M | +58.77% |
| Q3 2020 | 2020-09-30 | $335.5M | $35.6M | +11.87% |
| Q2 2020 | 2020-06-30 | $353.1M | $44.3M | +14.36% |
| Q1 2020 | 2020-03-31 | $372.8M | $130.6M | +53.94% |
| Q4 2019 | 2019-12-31 | $372.1M | $120.8M | +48.07% |
| Q3 2019 | 2019-09-30 | $299.9M | $104.9M | +53.81% |
| Q2 2019 | 2019-06-30 | $308.7M | $101.1M | +48.73% |
| Q1 2019 | 2019-03-31 | $242.1M | $25.0M | +11.50% |
| Q4 2018 | 2018-12-31 | $251.3M | $231.2M | +1147.40% |
| Q3 2018 | 2018-09-30 | $195.0M | $90.3M | +86.31% |
| Q2 2018 | 2018-06-30 | $207.6M | $96.5M | +86.89% |
| Q1 2018 | 2018-03-31 | $217.2M | $99.2M | +84.16% |
| Q4 2017 | 2017-12-31 | $20.1M | −$109.5M | −84.46% |
| Q3 2017 | 2017-09-30 | $104.7M | −$35.5M | −25.32% |
| Q2 2017 | 2017-06-30 | $111.1M | $11.2M | +11.23% |
| Q1 2017 | 2017-03-31 | $117.9M | $13.7M | +13.16% |
| Q4 2016 | 2016-12-31 | $129.6M | $16.3M | +14.41% |
| Q3 2016 | 2016-09-30 | $140.1M | $20.0M | +16.66% |
| Q2 2016 | 2016-06-30 | $99.9M | $48.2M | +93.18% |
| Q1 2016 | 2016-03-31 | $104.2M | $48.7M | +87.67% |
| Q4 2015 | 2015-12-31 | $113.3M | $107.8M | +1952.92% |
| Q3 2015 | 2015-09-30 | $120.1M | — | — |
| Q2 2015 | 2015-06-30 | $51.7M | — | — |
| Q1 2015 | 2015-03-31 | $55.5M | — | — |
| Q4 2014 | 2014-12-31 | $5.5M | — | — |
Rocket Pharmaceuticals total assets trends
Over the last five fiscal years, Rocket Pharmaceuticals's total assets decreased from $590.8M to $330.4M, a change of −$260.4M. The latest reported quarter, Q2 2026, shows $423.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rocket Pharmaceuticals source filings ↗